AllPennyStocks.com Sustainable Development ETF (SDG) Touches New 52-Week High
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Sustainable Development ETF (SDG) Touches New 52-Week High

For investors seeking momentum, the iShares MSCI Global Sustainable Development Goals ETF SDG is probably on the radar now. The fund just hit a 52-week high and rose 17.6% from its 52-week low price of $79.77 per share.

But are there more gains in store for this ETF? Let us take a quick look at the fund and its near-term outlook to get a better sense of where it might head.

SDG in Focus

The fund provides exposure to companies advancing sustainable themes in an equity portfolio. The fund charges 50 basis points (bps) in annual fees (See: all World ETFs here).

What Has Led to the Rise?

Strong earnings from the fund’s top holdings, including semiconductor heavyweights like Marvell Technology and NVIDIA, alongside healthcare giant Novartis and solar leader First Solar, provided significant upward momentum to SDF in recent times. Expanding institutional inflows into impact-focused ESG strategies must have continued to push the fund's net asset value to a new 52-week peak.

More Gains Ahead?

SDG may continue its strong performance in the near term, with a positive weighted alpha of 15.53 (per Barchart.com), which suggests a rally.

Boost Your Portfolio with Our Top ETF Insights

Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week.

Don’t miss out on this valuable resource. It’s free!

Get it now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
iShares MSCI Global Sustainable Development Goals ETF (SDG): ETF Research Reports

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Other Penny Stock Movers

65,000 Patients a Year, Zero Approved Drugs, One Phase 3 Trial
$4.5 Million Could Unlock a Major Cannabis Market
Chilean Gold Developer Gains 15% on Final Permit Clearance


Back to Top